The PrE0505 Study
Key Takeaways The PrE0505 study was a phase 2 clinical trial that tested the immunotherapy drug durvalumab combined with standard chemotherapy (pemetrexed and cisplatin) in patients with malignant pleural mesothelioma that could not be surgically removed. The results were significant: patients in the study had a median overall survival of 20.4 months — compared to […]
